Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.

Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD.

Nat Rev Drug Discov. 2005 Feb;4(2):131-44. Review.

PMID:
15665858
2.

Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

Palucha A, Pilc A.

Pharmacol Ther. 2007 Jul;115(1):116-47. Epub 2007 May 13. Review.

PMID:
17582504
3.

Metabotropic glutamate receptor 7: at the interface of cognition and emotion.

O'Connor RM, Finger BC, Flor PJ, Cryan JF.

Eur J Pharmacol. 2010 Aug 10;639(1-3):123-31. doi: 10.1016/j.ejphar.2010.02.059. Epub 2010 Apr 2. Review.

PMID:
20371242
4.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
5.

Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Nordquist RE, Steckler T, Wettstein JG, Mackie C, Spooren W.

Psychopharmacology (Berl). 2008 Aug;199(3):389-402. doi: 10.1007/s00213-008-1096-9. Epub 2008 Mar 6. Review.

PMID:
18322676
6.

The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration.

Tatarczyńska E, Kłodzińska A, Kroczka B, Chojnacka-Wójcik E, Pilc A.

Psychopharmacology (Berl). 2001 Oct;158(1):94-9.

PMID:
11685389
7.
8.

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.

Schoepp DD, Jane DE, Monn JA.

Neuropharmacology. 1999 Oct;38(10):1431-76. Review.

PMID:
10530808
9.

New therapeutic frontiers for metabotropic glutamate receptors.

Niswender CM, Jones CK, Conn PJ.

Curr Top Med Chem. 2005;5(9):847-57. Review.

PMID:
16178730
10.
11.

Physiological roles and therapeutic potential of metabotropic glutamate receptors.

Conn PJ.

Ann N Y Acad Sci. 2003 Nov;1003:12-21. Review.

PMID:
14684432
12.

Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.

Rouillon C, Degoulet M, Chevallier K, Abraini JH, David HN.

Brain Res. 2008 Mar 10;1198:44-54. doi: 10.1016/j.brainres.2008.01.025. Epub 2008 Jan 18.

PMID:
18261716
13.

Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.

Wierońska JM, Pilc A.

Neurochem Int. 2009 Jul-Aug;55(1-3):85-97. doi: 10.1016/j.neuint.2009.02.019. Epub 2009 Mar 9. Review.

PMID:
19428811
14.

Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.

Chaki S.

Eur J Pharmacol. 2010 Aug 10;639(1-3):59-66. doi: 10.1016/j.ejphar.2009.12.041. Epub 2010 Apr 2. Review.

PMID:
20371240
15.

Mood disorders: regulation by metabotropic glutamate receptors.

Pilc A, Chaki S, Nowak G, Witkin JM.

Biochem Pharmacol. 2008 Mar 1;75(5):997-1006. doi: 10.1016/j.bcp.2007.09.021. Epub 2007 Oct 5. Review.

PMID:
18164691
16.

Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.

Stachowicz K, Chojnacka-Wójcik E, Kłak K, Pilc A.

Neuropharmacology. 2007 Feb;52(2):306-12. Epub 2006 Oct 3.

PMID:
17020774
17.

Emerging signalling and protein interactions mediated via metabotropic glutamate receptors.

Moldrich RX, Beart PM.

Curr Drug Targets CNS Neurol Disord. 2003 Apr;2(2):109-22. Review.

PMID:
12769803
18.

Therapeutic potential of group III metabotropic glutamate receptors.

Lavreysen H, Dautzenberg FM.

Curr Med Chem. 2008;15(7):671-84. Review.

PMID:
18336281
19.

Are compounds acting at metabotropic glutamate receptors the answer to treating depression?

Palucha A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1545-53. Review.

PMID:
17107280
20.

Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Kew JN, Kemp JA.

Psychopharmacology (Berl). 2005 Apr;179(1):4-29. Epub 2005 Feb 25. Review. Erratum in: Psychopharmacology (Berl). 2005 Oct;182(2):320.

PMID:
15731895

Supplemental Content

Support Center